1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Human	_	_	JJ	_	_	_	_	_


1	T-lymphotropic	_	_	JJ	_	_	_	_	_
2	virus	_	_	NN	_	_	_	_	_
3	1	_	_	CD	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	HTLV-1	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	Deltaretrovirus	_	_	NNP	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	endemic	_	_	JJ	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	Japan	_	_	NNP	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	Caribbean	_	_	NNP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	South	_	_	NNP	_	_	_	_	_
18	America	_	_	NNP	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	Sub-Saharan	_	_	NNP	_	_	_	_	_
21	Africa	_	_	NNP	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	Melanesia	_	_	NNP	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	HTLV-1	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	associated	_	_	VBN	_	_	_	_	_
4	with	_	_	IN	_	_	_	_	_
5	several	_	_	JJ	_	_	_	_	_
6	different	_	_	JJ	_	_	_	_	_
7	types	_	_	NNS	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	diseases	_	_	NNS	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	Adult	_	_	JJ	_	_	_	_	_
2	T-cell	_	_	NN	_	_	_	_	_
3	leukemia/lymphoma	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	ATLL	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	develops	_	_	VBZ	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	up	_	_	IN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	5	_	_	CD	_	_	_	_	_
12	%	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	infected	_	_	VBN	_	_	_	_	_
15	people	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	sometimes	_	_	RB	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	chronic	_	_	JJ	_	_	_	_	_
21	neurodegenerative	_	_	JJ	_	_	_	_	_
22	inflammatory	_	_	JJ	_	_	_	_	_
23	disease	_	_	NN	_	_	_	_	_
24	called	_	_	VBN	_	_	_	_	_
25	HTLV-1-associated	_	_	JJ	_	_	_	_	_
26	myelopathy	_	_	NN	_	_	_	_	_
27	(	_	_	-LRB-	_	_	_	_	_
28	HAM	_	_	NN	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	develops	_	_	VBZ	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	high	_	_	JJ	_	_	_	_	_
4	percentage	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	people	_	_	NNS	_	_	_	_	_
7	remain	_	_	VBP	_	_	_	_	_
8	asymptomatic	_	_	JJ	_	_	_	_	_
9	during	_	_	IN	_	_	_	_	_
10	their	_	_	PRP$	_	_	_	_	_
11	lifetime	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	great	_	_	JJ	_	_	_	_	_
15	number	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	infected	_	_	VBN	_	_	_	_	_
18	people	_	_	NNS	_	_	_	_	_
19	develop	_	_	VBP	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	large	_	_	JJ	_	_	_	_	_
22	range	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	neurological	_	_	JJ	_	_	_	_	_
25	diseases	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Other	_	_	JJ	_	_	_	_	_
2	opportunistic-like	_	_	JJ	_	_	_	_	_
3	infections	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	such	_	_	JJ	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	Strongyloidiasis	_	_	NNP	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	Norwegian	_	_	JJ	_	_	_	_	_
10	scabies	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	infective	_	_	JJ	_	_	_	_	_
13	dermatitis	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	as	_	_	RB	_	_	_	_	_
16	well	_	_	RB	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	autoimmune	_	_	JJ	_	_	_	_	_
19	syndromes	_	_	NNS	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	including	_	_	VBG	_	_	_	_	_
22	rheumatoid	_	_	JJ	_	_	_	_	_
23	arthritis	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	Sjögren	_	_	NNP	_	_	_	_	_
26	’s	_	_	POS	_	_	_	_	_
27	syndrome	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	have	_	_	VBP	_	_	_	_	_
30	also	_	_	RB	_	_	_	_	_
31	been	_	_	VBN	_	_	_	_	_
32	described	_	_	VBN	_	_	_	_	_
33	among	_	_	IN	_	_	_	_	_
34	HTLV-1	_	_	NNP	_	_	_	_	_
35	carriers	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	these	_	_	DT	_	_	_	_	_
3	patients	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	clinical	_	_	JJ	_	_	_	_	_
7	conditions	_	_	NNS	_	_	_	_	_
8	appear	_	_	VBP	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	result	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	interaction	_	_	NN	_	_	_	_	_
16	between	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	virus	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	host	_	_	NN	_	_	_	_	_
22	susceptibility	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	leading	_	_	VBG	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	abnormal	_	_	JJ	_	_	_	_	_
28	functioning	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	immuno-modulatory	_	_	JJ	_	_	_	_	_
31	mechanisms	_	_	NNS	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	cell	_	_	NN	_	_	_	_	_
34	proliferation	_	_	NN	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	inflammation	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	HAM	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	chronic	_	_	JJ	_	_	_	_	_
5	progressive	_	_	JJ	_	_	_	_	_
6	demyelinating	_	_	JJ	_	_	_	_	_
7	disease	_	_	NN	_	_	_	_	_
8	that	_	_	WDT	_	_	_	_	_
9	affects	_	_	VBZ	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	spinal	_	_	JJ	_	_	_	_	_
12	cord	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	white	_	_	JJ	_	_	_	_	_
16	matter	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	brain	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	leading	_	_	VBG	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	severe	_	_	JJ	_	_	_	_	_
25	clinical	_	_	JJ	_	_	_	_	_
26	syndrome	_	_	NN	_	_	_	_	_
27	due	_	_	JJ	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	motor	_	_	NN	_	_	_	_	_
31	limitations	_	_	NNS	_	_	_	_	_
32	that	_	_	WDT	_	_	_	_	_
33	affect	_	_	VBP	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	lower	_	_	JJR	_	_	_	_	_
36	limbs	_	_	NNS	_	_	_	_	_
37	associated	_	_	VBN	_	_	_	_	_
38	with	_	_	IN	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	autonomic	_	_	JJ	_	_	_	_	_
41	dysfunction	_	_	NN	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	clinical	_	_	JJ	_	_	_	_	_
3	picture	_	_	NN	_	_	_	_	_
4	begins	_	_	VBZ	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	evolves	_	_	VBZ	_	_	_	_	_
7	insidiously	_	_	RB	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	being	_	_	VBG	_	_	_	_	_
10	difficult	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	establish	_	_	VB	_	_	_	_	_
13	when	_	_	WRB	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	first	_	_	JJ	_	_	_	_	_
16	symptoms	_	_	NNS	_	_	_	_	_
17	appeared	_	_	VBD	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	main	_	_	JJ	_	_	_	_	_
3	signs	_	_	NNS	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	symptoms	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	HAM	_	_	NN	_	_	_	_	_
8	may	_	_	MD	_	_	_	_	_
9	include	_	_	VB	_	_	_	_	_
10	gait	_	_	NN	_	_	_	_	_
11	disturbance	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	weakness	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	stiffness	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	lower	_	_	JJR	_	_	_	_	_
20	limbs	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	first	_	_	JJ	_	_	_	_	_
3	manifestations	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	disease	_	_	NN	_	_	_	_	_
7	occur	_	_	VBP	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	fourth	_	_	JJ	_	_	_	_	_
11	decade	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	life	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	there	_	_	EX	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	2:1	_	_	CD	_	_	_	_	_
19	woman/man	_	_	NN	_	_	_	_	_
20	ratio	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	incubation	_	_	NN	_	_	_	_	_
3	period	_	_	NN	_	_	_	_	_
4	differs	_	_	VBZ	_	_	_	_	_
5	from	_	_	IN	_	_	_	_	_
6	patient	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	patient	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	seems	_	_	VBZ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	be	_	_	VB	_	_	_	_	_
13	shorter	_	_	JJR	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	cases	_	_	NNS	_	_	_	_	_
17	where	_	_	WRB	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	virus	_	_	NN	_	_	_	_	_
20	was	_	_	VBD	_	_	_	_	_
21	acquired	_	_	VBN	_	_	_	_	_
22	through	_	_	IN	_	_	_	_	_
23	blood	_	_	NN	_	_	_	_	_
24	transfusion	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Two	_	_	CD	_	_	_	_	_
2	important	_	_	JJ	_	_	_	_	_
3	aspects	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	HAM	_	_	NNP	_	_	_	_	_
6	development	_	_	NN	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	been	_	_	VBN	_	_	_	_	_
9	reported	_	_	VBN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	including	_	_	VBG	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	efficiency	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	cellular	_	_	JJ	_	_	_	_	_
17	immune	_	_	JJ	_	_	_	_	_
18	response	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	rate	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	spontaneous	_	_	JJ	_	_	_	_	_
24	expression	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	viral	_	_	JJ	_	_	_	_	_
28	antigen	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	due	_	_	JJ	_	_	_	_	_
31	to	_	_	TO	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	numerous	_	_	JJ	_	_	_	_	_
34	immunological	_	_	JJ	_	_	_	_	_
35	alterations	_	_	NNS	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	mediated	_	_	VBN	_	_	_	_	_
38	mainly	_	_	RB	_	_	_	_	_
39	by	_	_	IN	_	_	_	_	_
40	the	_	_	DT	_	_	_	_	_
41	expression	_	_	NN	_	_	_	_	_
42	of	_	_	IN	_	_	_	_	_
43	Tax	_	_	NN	_	_	_	_	_
44	(	_	_	-LRB-	_	_	_	_	_
45	regulatory	_	_	JJ	_	_	_	_	_
46	protein	_	_	NN	_	_	_	_	_
47	of	_	_	IN	_	_	_	_	_
48	the	_	_	DT	_	_	_	_	_
49	virus	_	_	NN	_	_	_	_	_
50	)	_	_	-RRB-	_	_	_	_	_
51	in	_	_	IN	_	_	_	_	_
52	the	_	_	DT	_	_	_	_	_
53	peripheral	_	_	JJ	_	_	_	_	_
54	blood	_	_	NN	_	_	_	_	_
55	and	_	_	CC	_	_	_	_	_
56	in	_	_	IN	_	_	_	_	_
57	the	_	_	DT	_	_	_	_	_
58	cerebrospinal	_	_	JJ	_	_	_	_	_
59	fluid	_	_	NN	_	_	_	_	_
60	of	_	_	IN	_	_	_	_	_
61	patients	_	_	NNS	_	_	_	_	_
62	with	_	_	IN	_	_	_	_	_
63	HAM	_	_	NNP	_	_	_	_	_
64	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	order	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	control	_	_	VB	_	_	_	_	_
5	HTLV-1	_	_	NN	_	_	_	_	_
6	replication	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	proliferation	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	infected	_	_	VBN	_	_	_	_	_
12	cells	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	CD8+	_	_	NNP	_	_	_	_	_


1	T	_	_	NN	_	_	_	_	_
2	lymphocytes	_	_	NNS	_	_	_	_	_
3	mediate	_	_	VBP	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	main	_	_	JJ	_	_	_	_	_
6	defense	_	_	NN	_	_	_	_	_
7	strategy	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	host	_	_	NN	_	_	_	_	_
11	immune	_	_	JJ	_	_	_	_	_
12	system	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	HTLV-1	_	_	NNP	_	_	_	_	_
2	infects	_	_	VBZ	_	_	_	_	_
3	mainly	_	_	RB	_	_	_	_	_
4	CD4+	_	_	NNP	_	_	_	_	_
5	T	_	_	NNP	_	_	_	_	_
6	cells	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	which	_	_	WDT	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	central	_	_	JJ	_	_	_	_	_
12	regulators	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	acquired	_	_	VBN	_	_	_	_	_
16	immune	_	_	JJ	_	_	_	_	_
17	response	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	deregulating	_	_	VBG	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	host	_	_	NN	_	_	_	_	_
22	immune	_	_	JJ	_	_	_	_	_
23	system	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	establish	_	_	VB	_	_	_	_	_
3	persistent	_	_	JJ	_	_	_	_	_
4	infection	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	HTLV-1	_	_	NN	_	_	_	_	_
7	deregulates	_	_	VBZ	_	_	_	_	_
8	CD4+	_	_	NN	_	_	_	_	_
9	T	_	_	NN	_	_	_	_	_
10	cells	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	sometimes	_	_	RB	_	_	_	_	_
13	leading	_	_	VBG	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	ATLL	_	_	NNP	_	_	_	_	_
16	or	_	_	CC	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	chronic	_	_	JJ	_	_	_	_	_
19	inflammatory	_	_	JJ	_	_	_	_	_
20	diseases	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	such	_	_	JJ	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	HAM	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	uveitis	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	absence	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	symptoms	_	_	NNS	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	most	_	_	JJS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	infected	_	_	VBN	_	_	_	_	_
10	people	_	_	NNS	_	_	_	_	_
11	raises	_	_	VBZ	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	question	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	multiple	_	_	JJ	_	_	_	_	_
17	etiological	_	_	JJ	_	_	_	_	_
18	roles	_	_	NNS	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	virus-associated	_	_	JJ	_	_	_	_	_
22	diseases	_	_	NNS	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	some	_	_	DT	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	interesting	_	_	JJ	_	_	_	_	_
28	questions	_	_	NNS	_	_	_	_	_
29	still	_	_	RB	_	_	_	_	_
30	unanswered	_	_	JJ	_	_	_	_	_
31	includes	_	_	VBZ	_	_	_	_	_
32	:	_	_	:	_	_	_	_	_
33	does	_	_	VBZ	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	immunogenic	_	_	JJ	_	_	_	_	_
36	characteristics	_	_	NNS	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	host	_	_	NN	_	_	_	_	_
40	contribute	_	_	VB	_	_	_	_	_
41	to	_	_	TO	_	_	_	_	_
42	the	_	_	DT	_	_	_	_	_
43	upsurge	_	_	NN	_	_	_	_	_
44	of	_	_	IN	_	_	_	_	_
45	symptoms	_	_	NNS	_	_	_	_	_
46	associated	_	_	VBN	_	_	_	_	_
47	with	_	_	IN	_	_	_	_	_
48	HTLV-1	_	_	NNP	_	_	_	_	_
49	infection	_	_	NN	_	_	_	_	_
50	?	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	present	_	_	JJ	_	_	_	_	_
3	manuscript	_	_	NN	_	_	_	_	_
4	presents	_	_	VBZ	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	most	_	_	RBS	_	_	_	_	_
7	relevant	_	_	JJ	_	_	_	_	_
8	published	_	_	VBN	_	_	_	_	_
9	results	_	_	NNS	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	several	_	_	JJ	_	_	_	_	_
12	laboratories	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	including	_	_	VBG	_	_	_	_	_
15	ours	_	_	PRP	_	_	_	_	_
16	over	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	years	_	_	NNS	_	_	_	_	_
19	regarding	_	_	VBG	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	associations	_	_	NNS	_	_	_	_	_
22	between	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	genetic	_	_	JJ	_	_	_	_	_
25	variations	_	_	NNS	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	host	_	_	NN	_	_	_	_	_
29	related	_	_	VBN	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	immune	_	_	JJ	_	_	_	_	_
33	response	_	_	NN	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	HTLV-1	_	_	NN	_	_	_	_	_
36	infection	_	_	NN	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	particularly	_	_	RB	_	_	_	_	_
39	those	_	_	DT	_	_	_	_	_
40	showing	_	_	VBG	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	close	_	_	JJ	_	_	_	_	_
43	relationship	_	_	NN	_	_	_	_	_
44	between	_	_	IN	_	_	_	_	_
45	HTLV-1	_	_	NNP	_	_	_	_	_
46	infection	_	_	NN	_	_	_	_	_
47	and	_	_	CC	_	_	_	_	_
48	single	_	_	JJ	_	_	_	_	_
49	nucleotide	_	_	JJ	_	_	_	_	_
50	polymorphisms	_	_	NNS	_	_	_	_	_
51	in	_	_	IN	_	_	_	_	_
52	genes	_	_	NNS	_	_	_	_	_
53	of	_	_	IN	_	_	_	_	_
54	the	_	_	DT	_	_	_	_	_
55	immune	_	_	JJ	_	_	_	_	_
56	system	_	_	NN	_	_	_	_	_
57	.	_	_	.	_	_	_	_	_

